Balb c immunodeficient nude mice

Balb/c immunodeficient nude mice (Envigo, Loughborough, U.K.), between the ages of 6 and 8 weeks were used. Throughout the study, all mice were housed in air-conditioned rooms in facilities approved by the United Kingdom Home Office to meet all current regulations and standards. All procedures were carried out under a Project Licence (PPL 40/3670) issued by the UK Home Office according to government legislation, following approval of the work by the local Animal Welfare Ethics Review Board at the University of Bradford, and in accordance with the UK National Cancer Research Institute Guidelines for the Welfare of Animals17 (link). Tumour xenografts were established as previously described in the left and right flanks under brief general inhalation anaesthesia18 (link).

All procedures were carried out under Project Licence PPL 40/3670 issued by the UK Home Office according to government legislation, following approval of the work by the local Animal Welfare Ethics Review Board at the University of Bradford, and in accordance with the UK National Cancer Research Institute Guidelines for the Welfare of Animals^{37 (link)}. Balb/c immunodeficient nude mice (Envigo, Loughborough, UK), between the ages of 6 and 8 weeks, were used. Under brief general inhalation anaesthesia 2 to 3 mm³ fragments of U87-MG human tumor xenografts were implanted subcutaneously in the abdominal flank of the mice. Once tumour volumes reached approximately 32 mm³ (as measured by callipers), this was designated as Day 0, and mice were randomised into two groups (n = 8). One group received ICT-12035 administered intraperitoneally at 100 mg/kg dose on days 0, 1, 2, 3 and 4. For comparison, the control group was left untreated. Tumour volume using callipers and animal body weight were recorded through the experiment and normalised to the respective volume on the initial day of treatment (day 0). Mann–Whitney U tests were conducted to determine the statistical significance of any differences in growth rate (based on tumour volume doubling time) between control and treated groups.